. 2014 Nov 11;3(6):e001263. doi: 10.1161/JAHA.114.001263

Table 1.

Detailed Parameters of the Cell Surface Area and the Prevalence of Myofibrillar Disarray

	Control		HCM
	Cell Area	Myofibrillar Disarray	Cell Area	Myofibrillar Disarray
Figures 5C and 6D
Day 30	N=798 (sample size)	6.5% (prevalence) 55/851 (number of cardiomyocytes)	N=823	8.9% 84/947
	93 133 (mean)		109 933
	81 510 (median)		97 480
	61 200 to 109 930 (interquartile range)		69 245 to 132 820
Day 60	N=811	5.6% 49/875	N=816	9.2% 92/995
	92 636		112 592
	80 160		94 060
	58 760 to 110 940		68 560 to 140 740
Day 90	N=810	5.0% 47/932	N=821	9.3% 83/895
	91 319		113 097
	79 760		96 880
	61 140 to 107 120		67 230 to 13 0740
Figure 9B through E
Free (day 60)	N=811	5.6% 49/875	N=816	9.2% 92/995
	92 636		112 592
	80 160		94 060
	58 760 to 110 940		68 560 to 140 740
ET‐1	N=789	6.2% 59/955	N=809	20.6% 197/956
	102 499		135 038
	89 080		116 280
	68 200 to 119 120		85 120 to 165 690
Ang II	N=811	5.8% 51/883	N=788	9.2% 80/865
	94 848		121 538
	83 560		102 360
	61 400 to 117 220		77 100 to 144 250
IGF‐1	N=817	6.4% 58/903	N=810	10.1% 85/844
	97 786		120 339
	85 800		103 880
	65 600 to 113 480		77 160 to 140 470
PE	N=819	6.4% 56/870	N=819	10.3% 88/857
	99 371		120 147
	88 080		101 657
	66 900 to 118 200		70 160 to 143 130
Figure 12A and 12B
ET‐1, 0 nmol/L (day 60)	N=811	5.6% 49/875	N=816	9.2% 92/995
	92 636		112 592
	80 160		94 060
	58 760 to 110 940		68 560 to 140 740
ET‐1, 1.0 nmol/L	N=822	5.7% 51/889	N=818	13.8% 121/878
	94 228		122 839
	81 460		105 798
	61 920 to 112 045		72 355 to 154 155
ET‐1, 10 nmol/L	N=811	5.9% 52/878	N=822	16.7% 152/908
	98 535		127 885
	86 680		106 940
	64 920 to 118 350		77 380 to 152 398
ET‐1, 100 nmol/L	N=789	6.2% 59/955	N=809	20.6% 197/956
	102 499		135 038
	89 080		116 280
	68 200 to 119 120		85 120 to 165 690
ET‐1, 1000 nmol/L	N=810	6.4% 58/907	N=819	22.9% 204/892
	105 608		142 510
	94 040		122 040
	71 857 to 125 420		87 160 to 163 720
Figure 13B and 13C (graphs of control not shown)
Free (day 60)	N=811	5.6% 49/875	N=816	9.2% 92/995
	92 636		112 592
	80 160		94 060
	58 760 to 110 940		68 560 to 140 740
ET‐1	N=789	6.2% 59/955	N=809	20.6% 197/956
	102 499		135 038
	89 080		116 280
	68 200 to 119 120		85 120 to 165 690
ET‐1+ETA‐b	N=806	5.1% 47/916	N=817	10.4% 94/902
	91 901		116 527
	81 640		103 280
	63 515 to 108 460		73 200 to 140 880
ET‐1+ETB‐b	N=809	5.0% 43/866	N=821	17.3% 152/880
	98 786		132 030
	88 360		116 000
	66 880 to 116 400		81 010 to 159 690
ET‐1+ETA‐b+ETB‐b	N=808	5.5% 50/907	N=825	10.7% 98/917
	93 311		117 891
	83 300		100 800
	63 538 to 110 918		75 440 to 142 080
ETA‐b+ETB‐b	N=814	5.6% 52/927	N=823	9.5% 87/913
	92 227		110 616
	81 740		94 650
	62 760 to 108 855		65 360 to 138 800
Figure 14C and 14D (experiments in control not performed)
Free–free			N=300	13.9% 44/317
			137 988
			121 350
			89 755 to 159 190
Free–ET‐1			N=300	26.7% 92/344
			172 995
			160 570
			117 113 to 212 515
ET‐1–free			N=300	34.9% 126/361
			188 432
			158 215
			121 758 to 220 150
ET‐1–ETA‐b			N=300	20.8% 69/332
			142 950
			128 160
			96 530 to 174 118
Figure 15C and 15D	WT		HET
Control	N=176	4.7% 10/215	N=173	8.1% 18/223
	40 517		44 712
	38 073		45 126
	29 234 to 49 326		31 353 to 55 272
ET‐1	N=174	5.1% 12/236	N=178	15.5% 36/233
	52 694		57 824
	47 285		55 712
	35 484 to 68 430		43 746 to 69 539

HCM indicates hypertrophic cardiomyopathy; ET‐1, endothelin‐1; Ang II, angiotensin II; IGF‐1, insulin‐like growth factor‐1; PE, phenylephrine; ETA‐b, endothelin receptor type A blocker; ETB‐b, endothelin receptor type B blocker; HET, heterozygous Mybpc3‐targeted knock‐in mice; WT, wild‐type.